**Once again, the platelet is probably the wrong target…** Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non–Critically Ill Hospitalized Patients With COVID-19: A Randomized and Clinical Trial | Anticoagulation | JAMA | JAMA Network. jamanetwork.com/journals/jama/…
1
1
1
0
0
@2Scottish While P2Y12 inhibitors were not beneficial in moderate COVID - enrollment in severe patients is ongoing. Also, maybe crizanlizumab (Psel inhibitor) is a better target in #Covid_19 - Importance of #RCT in guiding clinical care @ACTIV4a @nih_nhlbi